Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

• Publication date

  2004-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.BIOPHA.2004.09.006PMID 15589067
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Worldwide Epidemiology of Obesity

  2012cited by this paper
• Statistics with Confidence (2nd ed.)

  2003cited by this paper
• Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

  2002cited by this paper
• Orlistat — A Novel Weight Loss Therapy

  2001cited by this paper
• A rapid and systematic review of the clinical effectiveness and cost-effectiveness of debriding agents in treating surgical wounds healing by secondary intention.

  2001cited by this paper
• A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.

  2001cited by this paper
• The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study

  2001cited by this paper
• Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.

  2000cited by this paper
• One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

  2000cited by this paper
• Obesity: preventing and managing the global epidemic. Report of a WHO consultation.

  2000cited by this paper
• Obesity : Preventing and managing the global epidemic

  2000cited by this paper
• Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.

  2000cited by this paper
• Effect of sibutramine on weight maintenance after weight loss: a randomised trial

  2000cited by this paper
• Antiobesity pharmacotherapy in the management of Type 2 diabetes

  2000cited by this paper
• Statistics with confidence

  2000cited by this paper
• Sibutramine produces dose-related weight loss.

  1999cited by this paper
• Sibutramine: A Serotonin–Norepinephrine Reuptake-Inhibitor for the Treatment of Obesity

  1999cited by this paper
• Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.

  1999cited by this paper
• Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients

  1998cited by this paper
• Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study

  1998cited by this paper
• Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study

  1998cited by this paper
• Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group.

  1998cited by this paper
• Treatment with orlistat reduces cardiovascular risk in obese patients

  1998cited by this paper
• Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study

  1998cited by this paper
• Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

  1998cited by this paper
• Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction?

  1998cited by this paper
• Sibutramine--a review of clinical efficacy.

  1997cited by this paper
• A prospective study of body mass index, weight change, and risk of stroke in women.

  1997cited by this paper
• A double-blind randomized placebo-controlled trial of sibutramine.

  1996cited by this paper
• The role of obesity in diabetes.

  1992cited by this paper
• Diet, nutrition, and the prevention of chronic diseases. Report of a WHO Study Group.

  1990cited by this paper
• Weight as a risk factor for clinical diabetes in women.

  1990cited by this paper
• WHO MONICA Project: risk factors.

  1989cited by this paper
• Goodman & Gilman's The Pharmacological Basis of Therapeutics

  1985cited by this paper
• Obesity as an Independent Risk Factor for Cardiovascular Disease: A 26‐year Follow‐up of Participants in the Framingham Heart Study

  1983cited by this paper
• The Pharmacological Basis of Therapeutics

  1976cited by this paper

• Black Ginger Extract Suppresses Fat Accumulation by Regulating Lipid Metabolism in High-Fat Diet-Fed Mice

  2024cites this paper
• Meta-analysis of the Effect of Orlistat on The Body Mass Index in Obese Subjects

  2022cites this paper
• The clinical efficacy of orlistat in the treatment of obesity

  2020cites this paper
• Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release

  2017cites this paper
• AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.

  2016cites this paper
• A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI

  2016cites this paper
• Pharmacogenetics of obesity drug therapy.

  2014cites this paper
• Modulation of fat digestion using bioactive alginates

  2014cites this paper
• Efficacy and safety of Chinese herbal medicine and acupuncture in the management of obesity: systematic reviews and a randomised placebo-controlled clinical trial

  2014cites this paper
• Medical Management of Obesity

  2014cites this paper
• The effectiveness of commercial weight loss programmes : a systematic review and evaluation of a pharmacist-led weight management clinic

  2013cites this paper
• Discovery of 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a novel peripherally restricted cannabinoid-1 receptor antagonist with significant weight-loss efficacy in diet-induced o

  2013cites this paper
• Effects of Physical Examination and Diet Consultation on Serum Cholesterol and Health-behavior in the Korean Pilots Employed in Commercial Airline

  2013cites this paper
• Efficacy and Safety of a Chinese Herbal Medicine Formula (RCM-104) in the Management of Simple Obesity: A Randomized, Placebo-Controlled Clinical Trial

  2012cites this paper
• What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.

  2012cites this paper
• Anti-Obesity Drugs: A Review about Their Effects and Safety

  2012cites this paper
• Orlistat

  2012cites this paper
• TRAMOMTANA ( Multidisciplinary treatment of morbid obesity : Medication , behavioral therapy , nutritional support , and physical activity ) . From question to reality in an investigator-initiated clinical trial ( II )

  2011cites this paper
• Obesity, adipose tissue and anti-obesity drugs

  2011cites this paper
• Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo.

  2011cites this paper
• TRAMOMTANA (Multidisciplinary treatment of morbid obesity: Medication, behavioral therapy, nutritional support, and physical activity). From question to reality in an investigator-initiated clinical trial (II)

  2011cites this paper
• The Pharmacological Treatment and Management of Obesity

  2011cites this paper
• [TRAMOMTANA (Multidisciplinary treatment of morbid obesity: medication, behavioral therapy, nutritional support, and physical activity). From question to reality in an investigator-initiated clinical trial (II)].

  2011cites this paper
• A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier.

  2011cites this paper
• Present and Future: Pharmacologic Treatment of Obesity

  2011cites this paper
• Sibutramine & naloxone: infra-additive interaction in the regulation of appetite?

  2010cites this paper
• Combinations of Drugs in the Treatment of Obesity

  2010cites this paper
• Efficacy and Tolerability of the Association of Sibutramine and Orlistat for Six Months in Overweight and Obese Patients

  2010cites this paper
• Long‐term changes in blood pressure following orlistat and sibutramine treatment: a meta‐analysis

  2010cites this paper
• Therapeutic options for the prevention of type 2 diabetes mellitus in the metabolic syndrome.

  2010cites this paper
• Pharmacological Approaches for Management of Child and Adolescent Obesity

  2010cites this paper
• Discovery of 1‐(2,4‐Dichlorophenyl)‐4‐ethyl‐5‐(5‐(2‐(4‐(trifluoromethyl)phenyl)ethynyl)thiophen‐2‐yl)‐N‐(piperidin‐1‐yl)‐1H‐pyrazole‐3‐carboxamide as a Potential Peripheral Cannabinoid‐1 Receptor Inverse Agonist

  2010cites this paper
• Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats.

  2010cites this paper
• Drugs Combinations in the Treatment of Obesity

  2010cites this paper
• Therapy of nonalcoholic fatty liver disease: current status.

  2009cites this paper
• How Physician Obesity Specialists Use Drugs to Treat Obesity

  2009cites this paper
• Orlistat: current status in clinical therapeutics

  2009cites this paper
• Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome.

  2009cites this paper
• Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice.

  2009cites this paper
• Current pharmacotherapeutic concepts for the treatment of obesity in adults

  2009cites this paper
• The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions.

  2009cites this paper
• Long-term administration of an aqueous extract of dried, immature fruit of Poncirus trifoliata (L.) Raf. suppresses body weight gain in rats.

  2009cites this paper
• The use of sibutramine in the management of obesity and related disorders: An update

  2009cites this paper
• Emerging concepts in the medical and surgical treatment of obesity.

  2008cites this paper
• Obesity and Its Treatment in Type 2 Diabetes

  2008cites this paper
• Nutrition in the metabolic syndrome: Pharmacological treatment

  2008cites this paper
• Central and peripheral neuroendocrine peptides and signalling in appetite regulation: considerations for obesity pharmacotherapy

  2008cites this paper
• Medikamente zur Behandlung von Esstörungen

  2008cites this paper
• Head‐to‐head studies evaluating efficacy of pharmaco‐therapy for obesity: a systematic review and meta‐analysis

  2008influential citation
• Bioisosteric replacement of the pyrazole 3-carboxamide moiety of rimonabant. A novel series of oxadiazoles as CB1 cannabinoid receptor antagonists.

  2008cites this paper
• Orlistat-Associated Adverse Effects and Drug Interactions

  2008cites this paper
• Pharmacotherapy for obesity in menopausal women

  2008cites this paper
• Effects of a Novel Y5 Antagonist in Obese Mice: Combination With Food Restriction or Sibutramine

  2008cites this paper
• Effects of a Novel Y5 Antagonist in Obese Mice: Combination With Food Restriction

  2008cites this paper
• An RCT of metformin versus orlistat for the management of obese anovulatory women.

  2008cites this paper
• Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage

  2007cites this paper
• NPY5R Antagonism Does Not Augment the Weight Loss Efficacy of Orlistat or Sibutramine

  2007cites this paper
• Critical assessment of the current guidelines for the management and treatment of morbidly obese patients

  2007cites this paper
• Inhibition of Dopamine and Norepinephrine Reuptake Produces Additive Effects on Energy Balance in Lean and Obese Mice

  2007cites this paper
• Obesity and pregnancy: A care plan for management

  2007cites this paper
• Antiobesity Pharmacotherapy: Current Treatment Options and Future Perspectives

  2007cites this paper
• Les médicaments de l’obésité

  2007cites this paper
• Pharmacological Treatment of the Overweight Patient

  2007cites this paper
• Adiposopathy: Treating pathogenic adipose tissue to reduce cardiovascular disease risk

  2007cites this paper
• Nutrition in Metabolic Syndrome Topic 24 Module 24 . 4 Pharmacological treatment

  2006cites this paper
• Pharmacologic treatment of obesity.

  2006cites this paper
• 5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents.

  2006cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  2006cites this paper
• Safety and Mechanism of Action of Orlistat (Tetrahydrolipstatin) as the First Local Antiobesity Drug

  2006cites this paper
• Nutrition in Metabolic Syndrome

  2006cites this paper
• Regulation der Nahrungsaufnahme: Physiologische Mechanismen und klinische Relevanz

  2005cites this paper
• The triad of type 2 diabetes, obesity and cardiovascular disease : investigating optimal dietetic treatment strategies.

  2005cites this paper
• The metabolic syndrome, hyperlipidemia, and insulin resistance.

  2005cites this paper
• A review of the metabolic effects of sibutramine

  2005cites this paper
• Vascular Health and Risk Management Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress the Use of Sibutramine in the Management of Obesity and Related Disorders: an Update

  year unknowncites this paper
• International Journal of Biological & Medical Research Obesity, Adipose Tissue and Anti-obesity Drugs a R T I C L E I N F O Review Article

  year unknowncites this paper